Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2021
FDA approves administration kit co-packaging for BERINERT
The FDA approved CSL Behring's supplemental request to co-package a convenience administration kit with BERINERT. The combined packaging was anticipated to be in-market within the third quarter of 2021.
2020
CSL Behring partners with SAB Biotherapeutics
CSL Behring partnered with US-based SAB Biotherapeutics under multiple collaboration and option agreements to explore potential therapies for autoimmune, infectious and idiopathic diseases using SAB's technology platform.
2020
SAB Biotherapeutics and CSL Behring announce research collaboration
SAB Biotherapeutics announced multiple collaboration and option agreements with CSL Behring to explore potential therapies for autoimmune, infectious and idiopathic diseases using SAB's DiversitAb platform. The companies will share research program and related costs and plan to complete the initial phase in 2020.